uMotif today announced a new investment of $25.5 million from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm. The new funding will support continued scale up of uMotif’s unique patient-first software platform for clinical research.
The company’s software is designed to provide pharmaceutical, biotech, medtech and Contract Research Organisation (CRO) clients with engaging patient data capture experience. It has been deployed in over 30 countries and helps clients simplify study design and reduce the burden on patients, through digital questionnaires and cloud technology.
uMotif will use the funding to support its international expansion and the continued development of its technologies, including solutions for pain, clinical outcome and symptom tracking. uMotif entered the US in 2021 and aims to grow its team there including in sales, marketing and service delivery.
Official comments
Steve Rosenberg, CEO of uMotif said: “We are delighted to welcome Athyrium to support our journey to be the most patient-centric platform for research. I truly believe that clinical research must put patients first, delivering more engaging research studies. With this investment from Athyrium I’m excited to grow our global capabilities to better serve our sponsors, partners and – most importantly – the patients we help take part in research.”
Mark Kavulich, Partner at Athyrium said: “Over recent years we have seen how the global eClinical market is significantly growing and quickly changing. uMotif’s approach to engaging patients in research is truly differentiated, patent-protected and is built on technology ready to scale. We’re excited to be joining the uMotif journey and supporting significant scale up in the coming years.”
